Literature DB >> 24024609

Systems Biology and Ratio-Based, Real-Time Disease Surveillance.

J M Fair1, A L Rivas2.   

Abstract

Most infectious disease surveillance methods are not well fit for early detection. To address such limitation, here we evaluated a ratio- and Systems Biology-based method that does not require prior knowledge on the identity of an infective agent. Using a reference group of birds experimentally infected with West Nile virus (WNV) and a problem group of unknown health status (except that they were WNV-negative and displayed inflammation), both groups were followed over 22 days and tested with a system that analyses blood leucocyte ratios. To test the ability of the method to discriminate small data sets, both the reference group (n = 5) and the problem group (n = 4) were small. The questions of interest were as follows: (i) whether individuals presenting inflammation (disease-positive or D+) can be distinguished from non-inflamed (disease-negative or D-) birds, (ii) whether two or more D+ stages can be detected and (iii) whether sample size influences detection. Within the problem group, the ratio-based method distinguished the following: (i) three (one D- and two D+) data classes; (ii) two (early and late) inflammatory stages; (iii) fast versus regular or slow responders; and (iv) individuals that recovered from those that remained inflamed. Because ratios differed in larger magnitudes (up to 48 times larger) than percentages, it is suggested that data patterns are likely to be recognized when disease surveillance methods are designed to measure inflammation and utilize ratios. Published 2013. This article is a U.S. Government work and is in the public domain in the USA.

Entities:  

Keywords:  Systems Biology; disease surveillance; early detection; epidemics; infections

Mesh:

Year:  2013        PMID: 24024609     DOI: 10.1111/tbed.12162

Source DB:  PubMed          Journal:  Transbound Emerg Dis        ISSN: 1865-1674            Impact factor:   5.005


  6 in total

1.  Visualizing the indefinable: three-dimensional complexity of 'infectious diseases'.

Authors:  Gabriel Leitner; Shlomo E Blum; Ariel L Rivas
Journal:  PLoS One       Date:  2015-04-14       Impact factor: 3.240

2.  Preventing Data Ambiguity in Infectious Diseases with Four-Dimensional and Personalized Evaluations.

Authors:  Michelle J Iandiorio; Jeanne M Fair; Stylianos Chatzipanagiotou; Anastasios Ioannidis; Eleftheria Trikka-Graphakos; Nikoletta Charalampaki; Christina Sereti; George P Tegos; Almira L Hoogesteijn; Ariel L Rivas
Journal:  PLoS One       Date:  2016-07-13       Impact factor: 3.240

Review 3.  Nature and Consequences of Biological Reductionism for the Immunological Study of Infectious Diseases.

Authors:  Ariel L Rivas; Gabriel Leitner; Mark D Jankowski; Almira L Hoogesteijn; Michelle J Iandiorio; Stylianos Chatzipanagiotou; Anastasios Ioannidis; Shlomo E Blum; Renata Piccinini; Athos Antoniades; Jane C Fazio; Yiorgos Apidianakis; Jeanne M Fair; Marc H V Van Regenmortel
Journal:  Front Immunol       Date:  2017-05-31       Impact factor: 7.561

4.  Assessing the Dynamics and Complexity of Disease Pathogenicity Using 4-Dimensional Immunological Data.

Authors:  Ariel L Rivas; Almira L Hoogesteijn; Athos Antoniades; Marios Tomazou; Tione Buranda; Douglas J Perkins; Jeanne M Fair; Ravi Durvasula; Folorunso O Fasina; George P Tegos; Marc H V van Regenmortel
Journal:  Front Immunol       Date:  2019-06-12       Impact factor: 7.561

5.  Multi-Cellular Immunological Interactions Associated With COVID-19 Infections.

Authors:  Jitender S Verma; Claudia R Libertin; Yash Gupta; Geetika Khanna; Rohit Kumar; Balvinder S Arora; Loveneesh Krishna; Folorunso O Fasina; James B Hittner; Athos Antoniades; Marc H V van Regenmortel; Ravi Durvasula; Prakasha Kempaiah; Ariel L Rivas
Journal:  Front Immunol       Date:  2022-02-24       Impact factor: 7.561

6.  Detecting the Hidden Properties of Immunological Data and Predicting the Mortality Risks of Infectious Syndromes.

Authors:  S Chatzipanagiotou; A Ioannidis; E Trikka-Graphakos; N Charalampaki; C Sereti; R Piccinini; A M Higgins; T Buranda; R Durvasula; A L Hoogesteijn; G P Tegos; Ariel L Rivas
Journal:  Front Immunol       Date:  2016-06-10       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.